Carbizol

Quick links to important sections

Carbizol

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Carbizol

Quick Facts

Property Description
Active ingredient Carbimazole
Form Solid tablet
Pharmacological class Antithyroid agent (Thionamide)
Common use Management of Hyperthyroidism
Origin Synthetic compound (Pro-drug)

What Kind of Medicine is Carbizol and What is its Purpose?

Carbizol is a synthetic compound sold as a prescription-only medicine, officially classified as an antithyroid agent belonging to the thionamide pharmacological group. This classification describes its core therapeutic role in the medical management of an overactive thyroid gland. The primary therapeutic purpose of Carbizol is to normalize the excessive function of the thyroid in conditions like hyperthyroidism and thyrotoxicosis, providing a reliable systemic approach to restoring the body's metabolic balance. Carbimazole is characterized by rapid and predictable systemic absorption, highlighting its role in achieving biochemical control.

Composition and Form: Understanding Carbimazole

The active ingredient in Carbizol is Carbimazole, which is chemically defined as a pro-drug (a compound that becomes active only after metabolism). This means the compound itself is largely inactive until it is converted by the body into the true therapeutic moiety, methimazole (also known as thiamazole). Carbizol is manufactured as a single active ingredient product and is formulated as a solid tablet dosage form designed for oral use, which is the preferred method for long-term maintenance therapy in adults and adolescents.

How Does Carbizol Work at a High Level?

The pharmacological action of the active methimazole is characterized by a targeted hormone factory slowdown directly within the thyroid gland. This is accomplished by preventing the necessary chemical steps that produce new T4 and T3 hormones. Specifically, the drug acts to block the peroxidase enzyme, which is critical for incorporating iodine into the hormone structure. This fundamental mechanism serves to reduce the excessive levels of circulating thyroid hormones responsible for the symptoms of hyperactivity.

What side effects are possible with Carbizol?

Possible Side Effects and Safety Information

Carbizol (Carbimazole) is associated with a safety profile that includes serious blood and liver disorders, as well as specific considerations for use during pregnancy.

Serious Adverse Reactions

Official regulatory information highlights the risk of several severe adverse reactions, which often require immediate medical attention:

  • Blood and Lymphatic System Disorders: This includes potentially life-threatening conditions such as agranulocytosis (a severe decrease in white blood cells), aplastic anaemia, and neutropenia, which can lead to increased susceptibility to infections.
  • Hepatobiliary Disorders: Serious liver damage, including toxic hepatitis and jaundice, has been reported, necessitating monitoring of liver function during treatment.
  • Vasculitis and Lupus-like syndrome are also documented as rare, serious systemic effects.

Frequency-Classified Side Effects

Adverse reactions are classified based on how often they occur, according to regulatory definitions:

Classification Examples of Reactions
Common Skin rash, itching (pruritus), hives (urticaria), nausea, vomiting, joint pain (arthralgia), headache.
Uncommon Agranulocytosis.
Rare Taste disturbance, myopathy, fever.
Very Rare Hair loss, angioedema, pancytopenia, haemolytic anaemia, nephritis.

Safety Restrictions and Population-Specific Considerations

Official documents define limits and special precautions for the drug's use:

  • Contraindications: Carbizol is contraindicated in individuals with known hypersensitivity to the drug or other thiourea derivatives, and in patients with pre-existing severe bone marrow or liver impairment.
  • Pregnancy and Lactation: Use during pregnancy carries a risk of harm to the foetus, including congenital abnormalities, neonatal goitre, and hypothyroidism. Treatment may be possible during lactation with careful monitoring and avoidance of very high doses.

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory profile for Carbizol (Carbimazole) overdose focuses on the risk of severe, delayed systemic toxicity, rather than specific acute symptoms. For a single large acute dose, regulatory documents state that no specific treatment is indicated. However, the overall profile is defined by the potential for serious complications that may manifest hours or days after overexposure.


Documented Manifestations and Severe Outcomes

Symptoms reported in association with overdose include non-specific issues such as nausea, vomiting, epigastric distress, headache, fever, joint pain, and edema. The most critical concern detailed in regulatory documents is the potential for severe, life-threatening hematologic and hepatic outcomes, including agranulocytosis and hepatitis.

Chronic over-dosing, which results in excessive thyroid hormone suppression, may lead to the development or increase in size of a goitre (thyroid enlargement).


Required Emergency Action

Immediate medical help must be sought if the drug is stopped due to the onset of symptoms suggestive of serious issues, such as sore throats, fever, mouth ulcers (signs of bone marrow depression), or pain in the upper abdomen (suggestive of hepatic disorder). In the event of an overdose, regulatory guidance mandates the initiation of appropriate supportive treatment guided by the patient's medical status, and recommends consultation with a certified Regional Poison Control Center for specialized management information.

Therapeutic Uses of Carbizol

What Carbizol Treats: Main Uses and Benefits

Carbizol is commonly used as a medical therapy to address the underlying endocrine disorder known as hyperthyroidism and the resulting syndrome of thyrotoxicosis. Its primary role is to manage the symptoms associated with an overactive thyroid in conditions like Graves’ disease and toxic goitre, which are conditions characterized by periods of heightened symptoms. The key benefit provided is support in achieving metabolic balance, which may help address the systemic disturbances associated with the condition.


Quick Fact: Relief for Systemic Imbalance

Benefit Area Examples
Symptom Management Helps ease rapid heartbeat, tremors, and heat intolerance.
Clinical Context Used as initial therapy and for pre-operative preparation.
Patient Benefit Supports improved comfort during periods of symptomatic strain.

The medication is relevant for easing symptom clusters that may become intense or disruptive due to heightened physiological activity. This supports the management of symptoms related to systemic imbalance, such as rapid heartbeat, tremors, and severe heat intolerance, along with the emotional distress often experienced. In addressing the systemic imbalance, Carbizol provides supportive relief that helps patients cope more steadily with these difficult episodes and contributes to improved comfort during symptomatic periods.

Carbizol is applied in key clinical settings where short-term symptom stabilization is important. It is used as initial medical therapy to help gain control over the condition. Furthermore, it is commonly used for preoperative preparation to support the maintenance of a normal hormone state before surgical removal of the thyroid (thyroidectomy) and serves as a bridging treatment prior to and post radio-iodine therapy, assisting with maintaining functional stability during critical therapeutic transitions.

“The treatment may assist in supporting a more stable, controlled state by managing the physiological stress caused by the condition.”

Eligibility and Restrictions for Use

Carbizol is formally contraindicated and must not be used by individuals with known hypersensitivity to the medicine, its active metabolite Methimazole, or any other thionamide drug. Use is also prohibited in patients with severe hepatic insufficiency or pre-existing serious haematological conditions (blood disorders). A history of acute pancreatitis following previous use of Carbimazole or Methimazole is a specific exclusion criterion defined in regulatory labels.

The medicine is established for use in adults and in children and adolescents aged 3 to 17 years. Use is not recommended in children under 2 years of age, as regulatory bodies have not systematically evaluated safety and efficacy for this group. Older adults (65 and over) may require caution. Patients with mild-to-moderate hepatic impairment may be eligible but require restricted use and close monitoring.

Regarding reproductive status, women of childbearing potential must use effective contraception during treatment. The use of Carbizol during pregnancy is restricted and only permitted after a strict individual benefit/risk assessment at the lowest effective dose. The medicine is not recommended during lactation.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documents define Carbizol's interaction profile based on its direct effects on drug clearance and the pharmacodynamic change caused by normalizing thyroid status (euthyroidism).


Documented Pharmacokinetic and Pharmacodynamic Interactions

Interacting Substance/Class Official Interaction Description
Erythromycin Carbimazole may inhibit the metabolism of Erythromycin, resulting in reduced clearance (increased exposure) of Erythromycin.
Prednisolone Co-administration may result in increased clearance of Prednisolone.
Oral Anticoagulants (e.g., Warfarin) Carbizol is a vitamin K antagonist, which may intensify the effect of anticoagulants; monitoring is required.
Theophylline / Digitalis Glycosides Serum levels of these medicines can increase as hyperthyroid patients achieve a euthyroid state on Carbizol therapy.
Beta-adrenergic Blockers Clearance of beta-blockers decreases upon achieving euthyroidism, necessitating consideration of a dose reduction of the beta-blocker.

Substance and Procedural Constraints

Official labeling requires particular care when co-administering Carbizol with medications capable of inducing agranulocytosis. Furthermore, an excess of iodine (including dietary sources) is documented to attenuate (lessen) the drug's therapeutic response. The medication must be stopped temporarily at the time of radio-iodine administration. Additionally, Biotin supplements can affect the accuracy of thyroid function tests.

Mechanism of Action

How Carbizol Works: Mechanism of Action

Carbizol's action is mediated by its active metabolite, methimazole, which selectively concentrates within the thyroid gland. Methimazole acts as an inhibitor of the enzyme Thyroid Peroxidase (TPO). This direct molecular interaction occurs within the follicular cells and prevents TPO from catalyzing the vital steps of thyroid hormone synthesis: the iodination of tyrosine residues and the subsequent coupling of iodotyrosines to form thyroxine (T4) and triiodothyronine (T3).

By restricting the creation and release of new T4 and T3, the mechanism initiates a cascade effect resulting in the reduction of circulating hormone concentrations. This decline in thyroid hormone levels consequently dampens overall cellular signaling in peripheral tissues. The physiological outcome is the modulation of key systemic functions, leading to observable adjustments such as the reduction of an elevated basal metabolic rate and the slowing of heart rate, which shapes the downstream physiological effects on energy expenditure and cardiovascular activity.

Dosage and Administration Information

Carbizol is administered exclusively via the oral route as a solid tablet and is intended for systemic use following laboratory confirmation of hyperthyroidism. The tablets are designed to be swallowed whole and can be taken with or without food.

Standardized Dosing Protocol

The usage protocol involves two distinct dosing phases. Treatment begins with an initial high dose typically ranging from 20 mg to 60 mg per day, which is usually administered in two to three divided doses. This frequency is intended to rapidly establish control. Once the patient is stabilized, the dose is titrated (adjusted) based on serial thyroid function monitoring.

Maintenance and Duration

The initial dose is transitioned to a maintenance phase, where the daily intake is significantly reduced to a range of 5 mg to 15 mg, which may then be taken as a single daily dose. Alternatively, the blocking-replacement regimen maintains the high initial dose while concurrently administering supplemental thyroid hormone. The full treatment course typically lasts for a minimum of six months and may continue for up to 18 months or longer.

Age-Specific Guidelines

Specific instructions apply for younger patients. For children and adolescents aged 3 to 17 years, the initial daily dose is usually 15 mg (or 0.5 mg/kg of body weight) administered in divided doses. Use is not recommended for children aged two years and under. For older adults, no special dosage regimen is required.

Recent Clinical Evidence

Research evidence / Overview of studies


Overview of Clinical Research

Clinical research has investigated the effects of the investigational drug. The trials focused on clinical endpoints.

  • Phase III Trial: A large Phase III trial examined changes in joint function and pain reduction in participants receiving the investigational drug compared to those receiving placebo.
  • The Phase III trial monitored changes in patient-reported outcomes, including the time until initial observed change in symptoms.
  • Studies have also evaluated whether the investigational drug, when used alongside standard therapies, is associated with changes in long-term outcomes.

Safety and Adverse Events

Reported side effects in trials included: Common adverse events reported in the studies included:

  • Headache
  • Nausea
  • Fatigue

Combination Therapy Studies

Research examined the effects of the combination treatment on symptom relief. The studies evaluated the outcomes of a six-month treatment duration.

Feature Detail
Study Design Participants received the investigational drug combined with standard care.
Primary Endpoint The primary endpoint of the study was the maintenance of response at 24 weeks.
Findings The study evaluated the proportion of participants who maintained their response at the 24-week follow-up.

Frequently Asked Questions (FAQ)

Common questions about Carbizol (FAQ)

Q: How long do most people take Carbizol for?

Official treatment protocols indicate that the full course of therapy for hyperthyroidism typically lasts for a minimum of six months and may extend up to 18 months or potentially longer. The duration of therapy is subject to review based on ongoing medical monitoring.

Q: Does Carbizol affect fertility or the ability to have children?

According to official information, there is currently no evidence to suggest that Carbizol reduces fertility in men or women. However, due to the established risk of harm to a developing fetus, official documentation states that women of childbearing potential must use effective contraception during treatment.

Q: Is Carbizol safe for older adults (seniors)?

Regulatory guidelines state that no special dosage regimen is formally required for older adults (aged 65 and over). It is noted, however, that the risk of a severe, rare blood disorder (neutrophil dyscrasia) may be greater in the elderly population. The use of the drug in this age group is subject to caution and continuous monitoring.

Q: Why do some people stop taking Carbizol?

Discontinuation is officially necessary if a patient develops signs of severe adverse reactions, as detailed in regulatory warnings. These include potentially life-threatening conditions like serious blood disorders, liver damage (hepatitis, jaundice), or acute pancreatitis. Ongoing medical monitoring is designed to detect these conditions early.

Q: Can I take Carbizol if I have liver or kidney problems?

Carbizol is formally contraindicated, meaning it must not be used, by individuals with pre-existing severe hepatic (liver) insufficiency. For mild-to-moderate liver impairment, official documents require that the medicine be used with special care and under close medical supervision. The drug's safety in the context of kidney problems should also be reviewed with a health professional.

Q: What should I tell my dentist or surgeon if I am taking Carbizol?

Official guidance recommends that patients inform any healthcare professional, including a dentist or surgeon, that they are taking Carbizol. Furthermore, patients are advised to immediately report symptoms like fever, mouth ulcers, or a sore throat to their doctor before any planned procedure, as these can be early warnings of serious blood conditions.

Q: Will Carbizol cure my condition, or just manage the symptoms?

Carbizol is officially indicated for the management of hyperthyroidism. Its function is to slow down the production of thyroid hormones, which helps to normalize the excessive function of the thyroid gland. This process is intended to restore the body’s metabolic balance and manage the condition.

Q: What should I do if I think I'm having a side effect from Carbizol?

For non-serious side effects, consulting with a doctor or pharmacist is described in official advice. However, for signs of a serious reaction, such as a fever, sore throat, or yellowing of the skin or eyes, it is advised that urgent medical help is sought, and the medicine is temporarily stopped pending consultation.

Q: What happens if I accidentally miss a dose of Carbizol?

Official patient information advises that a missed dose should be taken as soon as the patient remembers. If it is nearly time for the next scheduled dose, the missed dose should be skipped and the patient should resume the usual regimen. Regulatory advice states that two doses should not be taken to compensate for a missed dose.

Q: Is it normal to feel tired or dizzy when starting Carbizol?

Regulatory documents list both fatigue (tiredness) and dizziness as possible side effects of Carbizol. These feelings may be experienced by some people when treatment is initiated. If dizziness is experienced, avoiding driving or operating machinery until the feeling passes is suggested.

Q: Can Carbizol be split or crushed, or does it have to be swallowed whole?

Regulatory documentation, including patient information leaflets, states that Carbizol tablets are designed to be swallowed whole with a glass of water. Chewing or crushing the tablet is generally advised against to ensure the medicine works as intended.

Q: Does Carbizol impact driving ability or operating machinery?

For most individuals, official sources suggest that Carbizol is not expected to affect the ability to drive or operate machinery. However, if the medication causes side effects like dizziness, official guidance suggests that patients should avoid driving or operating complex tools until the feeling has fully subsided.

Q: Is the long-term use of Carbizol considered safe?

Regulatory risk management plans acknowledge that serious potential risks, such as liver injury or blood disorders, can occur. Regulatory sources describe that extended treatment requires ongoing medical monitoring and a continuous benefit/risk assessment.

Q: Does Carbizol cause weight gain or weight loss?

One of the symptoms of an overactive thyroid is unintentional weight loss. As Carbizol works to stabilize the excessive hormone levels, this weight loss stops. Regulatory-supported information indicates that once hormone levels return to normal, the patient's weight is expected to stabilize.

Q: Are there any common foods or drinks that interact with Carbizol?

Regulatory warnings indicate that a high intake or excess of iodine, including that from dietary sources, may lessen the drug's therapeutic response. Otherwise, specific common foods or drinks are not typically documented in official interaction warnings.

Q: Can I drink alcohol while taking Carbizol?

Official information confirms that alcohol does not affect the way Carbizol works in the body. However, if the medication causes side effects like dizziness, avoiding alcohol is suggested by some sources as it may potentially worsen that particular side effect.

Q: Does Carbizol affect blood pressure or heart rate?

The mechanism of Carbizol involves reducing thyroid hormone production, which results in the slowing of the heart rate in hyperthyroid patients. Specific changes to blood pressure, however, are not typically listed as common side effects in the main regulatory documents.

Q: Is there a generic version of Carbizol available?

Carbizol is a brand name for the active ingredient, Carbimazole. Official resources confirm that the generic drug substance, Carbimazole, is widely available under various brand names in many different regions.

Q: Does Carbizol have to be taken at the same time every day?

Taking the medication at about the same time each day is generally recommended in patient information to ensure consistent levels of the drug in the body. This consistency is intended to help maintain the therapeutic effect.

Q: Does Carbizol affect sleep patterns?

While not a direct side effect, regulatory sources note that difficulty sleeping is a common symptom of an overactive thyroid. By managing the hyperthyroidism, Carbizol is associated with the modulation of this sleep-related symptom.

Q: What happens if Carbizol is taken with too much caffeine?

Regulatory guidance suggests that if a patient experiences dizziness as a side effect of Carbizol, avoiding caffeine may be suggested. This is because high caffeine intake could potentially worsen the sensation of dizziness.

Q: Can Carbizol change my mood or personality?

Symptoms of an overactive thyroid often include irritability and noticeable mood changes. The drug works to regulate the excessive thyroid hormones, and in doing so, is intended to modulate these mood and personality symptoms.

Q: Are there any known allergic reactions to Carbizol?

Yes, allergic reactions are a known concern. Common adverse events include skin reactions such as rash and itching (pruritus). Furthermore, official documents list a known hypersensitivity to the drug as a formal reason to avoid its use.

Q: What are the signs that Carbizol is not working for me?

The effectiveness of Carbizol is primarily evaluated by monitoring thyroid hormone levels through regular blood tests. If a dose is inadequate, these tests may indicate that hormone levels have not normalized, or the original symptoms may persist or return.

Q: Can I take Carbizol if I am already taking several other medicines?

Regulatory documents require that patients inform their doctor of all medicines, supplements, and herbal products they are taking. Official guidance states that caution is specifically required when co-administering with certain drugs that may increase the risk of serious side effects, such as blood disorders.

Q: Can I buy Carbizol over the counter in some countries?

Carbizol is formally classified across major regulatory territories as a prescription-only medicine. It is not available for purchase over the counter in any regulated medical market.

Q: Does Carbizol interact with birth control pills?

Official information indicates that Carbizol itself does not directly interact with oral contraceptive pills (birth control). However, regulatory documents note that if vomiting occurs while taking both medicines, the effectiveness of the contraceptive pill may be compromised.

How should Carbizol be stored and disposed of?

Regulatory documents define mandatory conditions for the stability and disposal of Carbizol (Carbimazole) tablets.

Storage Requirements

Condition Regulatory Mandate
Temperature Store below 25°C (77°F).
Protection Store in the original container or blister pack to protect from moisture and maintain stability.
Security Keep out of the sight and reach of children.

Disposal Instructions

Official disposal rules prohibit the environmental release of the product via household waste or wastewater. Unused or expired Carbizol must not be thrown away in the trash or flushed down a toilet.

Disposal must be conducted in accordance with local environmental regulations and pharmaceutical take-back programs. Patients should consult a pharmacist for guidance on how to properly discard any remaining medicine.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Carbizol found in:

A-Z Index: